NCT00522145View on ClinicalTrials.gov

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

February 28, 2010

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

XL647

Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets

Trial Locations (10)

10021

Memorial Sloan-Kettering Cancer Center, New York

21740

Washington County Hospital, The Center for Clinical Research, Hagerstown

28560

New Bern Cancer Care Oncology, New Bern

44106

Case Western Reserve University, University Hospitals of Cleveland, Cleveland

45042

Signal Point Clinical Research Center, Middletown

47150

Cancer Care Center, Inc. P.C., New Albany

48201

Wayne State University, Wertz Clinical Cancer Center, Karmanos Center, Detroit

94305

Oncology Division and General Clincial Research, Stanford University Medical Center, Stanford

95020

Ronald Yanagihara, Gilroy

95817

University of California Davis Cancer Center, Sacramento

All Listed Sponsors
lead

Kadmon Corporation, LLC

INDUSTRY

NCT00522145 - Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib | Biotech Hunter | Biotech Hunter